Author, Medical Expert and Entrepreneur-Clay Siegall – Seattle Genetics’ CEO

Cancer has been a menace to the world and scientists have been conducting extensive research to get the treatment of the illness. The studies conducted over the years have given hope to the individuals who have cancer for natural ways that do not cause greater losses in their health have been innovated.
One of the most renowned scientists is Dr. Clay Siegall; he has been at the forefront of conducting extensive researches to assist the cancer patients. To be able to offer quality medical services to the cancer patients, Clay Siegall established Seattle Genetics in 1998. Clay is the president, the Chief Executive Officer and he serve as the Chairman of the Board of Directors. Dr. Siegall is a scientist by training, and he specializes in the cancer treatment. He built his firm on the foundations of scientific innovations, rigorous research and drug development practice as well as the passion for assisting the cancer patients.
Clay Siegall has excellent leadership skills that have enabled him to guide the company through the development of Anti-drug Conjugates (ADC), and he has also led the company in securing the approval of 2011 FDA for its ADC product ADCETRIS. Seattle has joined with Takeda Pharmaceuticals Company to distribute the drug to the world, and it has its distribution to more than 60 countries in the world. Under the leadership of Clay, the company has entered into a partnership with other pharmaceuticals organizations including Genentech, AbbVie, GlaxoSmithKline as well as Pfizer. Before the foundation of Seattle Genetics Dr. Siegall worked at Bristol Meyers Pharmaceuticals Research Institute between 1991 and 1997 he also worked at National Cancer Institute, and National Institute of Health.
His leadership skills have seen him hold various positions in several Board of Directors including Ultragenyx Pharmaceuticals, Mirna Therapeutics, Washington RoundTable and Alder Biopharmaceuticals. Clay is a go-getter and has been part of several awards including University of Maryland Alumnus of the year for computer, math, and natural sciences; he was awarded the Pacific Ernst & Young Entrepreneur of the year awards. Clay can be described as a jack of all trades, and he is also a publisher who has published more than70 publications and held more than 15 patents. He is Ph.D. Holder from the George Washington University and has B.S in Zoology from the University of Maryland.


Dr. Siegall is a trained scientist who focuses much on the targeted cancer therapies. He is also the co-founder to Seattle Genetics Company established in 1998. Dr. Siegall currently serves the Company’s Chairman of it board, the President and also the Company’s CEO.
Seattle Genetics Company, based in Bethel, is setting the trends in cancer research. Under the direction of Clay Siegull, the company has is pushing its limits by selling one of its cancer drugs (Adcetris) used largely to fight lymphomas, to a tune of up to 226 million dollars in the United States and Canadian sales last year. These figures are on the rise this year with speculations of a range of $255 million to $275 million.
This drug is not the only one the company has in store for us, according to Clay Siegall, there are still twelve developments (excluding Ancestry). Short term goals for the company are to push for another drug- 33A, into Phase 3 clinical trials this year. The drug will be used to treat acute myeloid leukemia. Also, there is also a drug for breast cancer and two drugs for bladder cancer. Which are going to be released and data on them given?
Under Dr. Siegall’s leadership the Company performed several activities to raise capital. The company has secured over 675 million US dollars through financings both private and public, inclusive the initial public offering of the company in 2001. Aside from this, the company is creating a lot of employment opportunities and is upfront in customer satisfaction and care.
Dr. Siegall apart from leading the Seattle Genetics Company to greatness, he serves in various capacities as he is on the Directors Board of Mirna Therapeutics, Alder Biopharmaceuticals among others. Dr. Siegall has also awarded several prizes such from the University of Maryland and the Young 2012’s year Entrepreneur and Pacific Northwest Ernst. Dr. Siegall is also an author of not just one, but more than seventy publications and holds fifteen patents.